Prospective Grant of Exclusive License: Pigment Epithelium Derived Growth Factor

Resumo

This notice, in accordance with 35 U.S.C. 209(c)(1) and 37 CFR 404.7(a)(1)(I), announces that the National Institutes of Health is contemplating the grant of an exclusive world-wide license to GenVec, Inc., a Delaware corporation headquartered in Rockville, Maryland to practice the inventions embodied in the U.S. Patent Applications listed below (and corresponding foreign patent applications) in the field of ocular gene therapy. These inventions are owned by the Government of the United States of America as represented by the Department of Health and Human Services. 1. USSN 07/952,796 entitled ``DNA Clones for the Expression of Pigment Epithelium Derived Growth Factor and Related Proteins'' filed September 24, 1992 by Fintan R. Steele, Gerald J. Chader, Joyce Tombran-Tink and Sofia P. Becerra. 2. USSN 08/257,963 entitled ``Pigment Epithelium Derived Factor: Characterizations of Its Biological Activity and Sequences Encoding and Expressing the Protein'' filed June 7, 1994 by Gerald J. Chader, Sofia P. Becerra, Joan P. Schwartz, Takayuki Taniwaki and Yukihera Sugita. 3. USSN 08/279,979 entitled ``Retinal Pigmented Epithelium Derived Neurotrophic Factor'' filed July 25, 1994 by Fintan